Arcus Biosciences Inc (RCUS)

NYSE · Healthcare · Biotechnology · USA

Arcus Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Arcus Biosciences is a late-stage biopharmaceutical company developing small-molecule therapies for cancer and inflammatory and autoimmune diseases. Its oncology pipeline includes casdatifan for renal cell carcinoma, quemliclustat for pancreatic cancer, domvanalimab and zimberelimab for various cancers, with registrational studies underway. The company also has discovery programs targeting inflammation and autoimmune conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Arcus Biosciences Inc stock.

Our verdict on RCUS

Overvalued: intrinsic value $3.47 per share, market price $16.39, margin of safety -372.9% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $3.47; the price of $16.39 is 373% above that value.

ETFs with the most weight in RCUS

17 more funds hold it; the full list is part of the paid plan.

More on RCUS

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than RCUS in Biotechnology

83 more in this industry show a wider margin of safety.

Is RCUS undervalued or overvalued?

RCUS is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $3.47; the price of $16.39 is 373% above that value.

What is the intrinsic value of RCUS?

$3.47 per share (as of the 2026-11-17 close), against a market price of $16.39. That is a margin of safety of -372.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.